NF-κB as a therapeutic target in cancer
- 1 August 2002
- journal article
- review article
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 8 (8), 385-389
- https://doi.org/10.1016/s1471-4914(02)02375-4
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κBJournal of Clinical Investigation, 2001
- Role of NF-κB in p53-mediated programmed cell deathNature, 2000
- Phosphorylation Meets Ubiquitination: The Control of NF-κB ActivityAnnual Review of Immunology, 2000
- Aberrant rel/nfkb genes and activity in human cancerOncogene, 1999
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- The role of the ubiquitin-proteasome pathway in apoptosisCell Death & Differentiation, 1999
- NF-κB AND REL PROTEINS: Evolutionarily Conserved Mediators of Immune ResponsesAnnual Review of Immunology, 1998
- Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells.Journal of Clinical Investigation, 1997
- The role of Rel/NF-κB proteins in viral oncogenesis and the regulation of viral transcriptionSeminars in Cancer Biology, 1997
- THE NF-κB AND IκB PROTEINS: New Discoveries and InsightsAnnual Review of Immunology, 1996